How can hospitals make the post-merger transition as smooth as possible?

The latest stories trending on MedCity News.

Editor's Pick

Top Story How Can Hospitals Make the Post-Merger Transition As Smooth As Possible? Experts have predicted that 2024 will be an eventful year for hospital M&A activity. As the industry prepares for another big year, there are a few things that health system leaders involved in these deals should keep in mind to make the process as smooth as possible, according to DexCare CEO Derek Streat. Sponsored Content Heard at HLTH: Clarify Health Presented by Clarify Health Todd Gottula, President and co-founder on how Clarify Health's analytics tools can help payers review performance of hospitals in their network. Watch the full interview here. Calling Startups We're looking for a few good startups in oncology, cardiology, women's health, and burnout/operational efficiency. Select your track, each track will feature 6 finalists for INVEST 2024. Deadline to apply is February 29, 2024. There is no fee to apply. Apply Now

Featured News

KPMG: Tailwinds and Headwinds for Payers in 2024 A recent KPMG report laid out several tailwinds and headwinds for payers in 2024. Payers' tailwinds include reduced recession worries, while their headwinds include Medicare Advantage scrutiny. How Strong Cybersecurity Hygiene Can Help Rural Healthcare Systems Hack off the Hackers Protecting rural healthcare and pharmaceutical networks is an ongoing effort that requires comprehensive cybersecurity that goes beyond traditional IT systems, combining technical solutions, employee education, and a commitment to staying up to date with evolving cyber threats. Health System Credit Downgrades: Unpacking the Challenges and Exploring Solutions The significance of credit ratings for health systems cannot be overstated. They serve as a warning sign indicating organizations need to transform. Health systems can no longer rely on top-line revenue to address their inherited problems. It is clear that a fresh approach to cost management is required to break away from past practices and chart a new course toward financial viability and sustainability. With Phase 3 Studies Ongoing in Bladder Cancer, CG Oncology Plots Course for IPO CG Oncology's main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follow the report of interim efficacy data showing a 75% complete response rate.

Resources

How To Enable a Hyperpersonal Care Experience This on-demand webinar features expert panelists from Praia Health and Providence, interviewed by AVIA to discuss the benefits of adopting a hyperpersonal care model for patients, barriers that hold health systems back, and will unpack Praia Health's technology capabilities. Watch Now

MedCity News • PO Box 901 • New York, NY unsubscribe